Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
Alnylam Pharmaceuticals, Inc. announced today that it has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"Execution of this license agreement with Bio-Rad, a global leader in the life science research community, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG. "This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Revealing DNA behavior in record time
DataApex audited for ISO 9001 standards
Brain imaging gives new insight into mental disorders
Pain sensors specialized for specific sensations
Corona research at BESSY II: Two days of measuring operation to find the right key
Sensor to search for artery hardening compounds in blood
Potent, puzzling and (now less) toxic: How antifungal drug works
Merck’s new spin-off to focus on infertility treatment
Rapid imaging of granular matter
Millipore Corporation's re-branding underscores expanded capabilities and partnership with customers - Millipore Foundation awards $500,000 research gift to the Harvard Stem Cell Institute
Molecular motion in tire rubber - Tyre components observed with incredible time resolution
